Olpasiran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Cardiovascular DiseaseCardiovascular Events

147 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

1

Geodon

Pfizer

Approved

—2

Cardene

Sun Pharmaceutical Industries, Inc.

Approved

—3

Primacor

Sanofi

Approved

—4

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—5

Midamor

PPadagis LLC

Approved

—6

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—7

Giapreza

LLa Jolla Pharmaceutical Company

Approved

—8

Colcrys

Jazz Pharmaceuticals

Phase 3

19

Cagrilintide

Novo Nordisk

Phase 3

110

Pelacarsen

Novartis

Phase 3

1Show 45 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cardiovascular Events2 trials

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Not yet recruiting·Amgen·Phase 3·NCT07293260·406 enrolled

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Completed·Amgen·Phase 2·NCT04270760·281 enrolled

ESS1 trial

Olpasiran Expanded Access Program

Available·Amgen··NCT07079267

Tics1 trial

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Completed·Amgen·Phase 1·NCT04987320·24 enrolled

Hepatic Impairment1 trial

A Phase I, Open-label Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Various Degrees of Hepatic Impairment

Completed·Amgen·Phase 1·NCT05481411·25 enrolled

Atherosclerotic Cardiovascular Disease1 trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

Active, not recruiting·Amgen·Phase 3·NCT05581303·7,297 enrolled

3 more indications

Renal Impairment1 trial

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal Impairment

Completed·Amgen·Phase 1·NCT05489614·33 enrolled

Basic Science1 trial

A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

Completed·Amgen·Phase 1·NCT06411860·32 enrolled

Cardiovascular Disease1 trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Recruiting·Amgen·Phase 3·NCT07136012·11,000 enrolled

Details

Drug Info

Related News